Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Head and Neck Cancer

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 389 articles:
HTML format
Text format



Single Articles


    October 2019
  1. WU LR, Zhang XM, Xie XD, Lu Y, et al
    Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with 10-year follow-up.
    Oral Oncol. 2019;98:141-146.
    PubMed     Text format     Abstract available


    September 2019
  2. LI M, Chen H, Wu T
    LIN28: A cancer stem cell promoter for immunotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2019;98:92-95.
    PubMed     Text format     Abstract available


  3. YANG K, Tian J, Zhang B, Li M, et al
    A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2019;98:85-91.
    PubMed     Text format     Abstract available


  4. HAAPANIEMI A, Makitie A, Kekolahti P, Ryynanen OP, et al
    A preliminary Bayesian network model to identify factors associated with treatment outcome in T2 and T3 laryngeal carcinoma.
    Oral Oncol. 2019 Sep 25. pii: S1368-8375(19)30306.
    PubMed     Text format    


  5. DENG J, He Y, Sun XS, Li JM, et al
    Construction of a comprehensive nutritional index and its correlation with quality of life and survival in patients with nasopharyngeal carcinoma undergoing IMRT: A prospective study.
    Oral Oncol. 2019;98:62-68.
    PubMed     Text format     Abstract available


  6. DE MARCHI P, Melendez ME, Laus AC, Kuhlmann PA, et al
    The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer.
    Oral Oncol. 2019;98:48-52.
    PubMed     Text format     Abstract available


  7. VAN HARTEN AM, Poell JB, Buijze M, Brink A, et al
    Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
    Oral Oncol. 2019;98:53-61.
    PubMed     Text format     Abstract available


  8. DIONISI F, Fiorica F, D'Angelo E, Maddalo M, et al
    Organs at risk's tolerance and dose limits for head and neck cancer re-irradiation: A literature review.
    Oral Oncol. 2019;98:35-47.
    PubMed     Text format     Abstract available


  9. LIN C, Puram SV, Bulbul MG, Sethi RK, et al
    Elective neck dissection for salvage laryngectomy: A systematic review and meta-analysis.
    Oral Oncol. 2019;96:97-104.
    PubMed     Text format     Abstract available


  10. JAJODIA A, Aggarwal D, Chaturvedi AK, Rao A, et al
    Value of diffusion MR imaging in differentiation of recurrent head and neck malignancies from post treatment changes.
    Oral Oncol. 2019;96:89-96.
    PubMed     Text format     Abstract available


  11. SALOURA V, Izumchenko E, Zuo Z, Bao R, et al
    Immune profiles in primary squamous cell carcinoma of the head and neck.
    Oral Oncol. 2019;96:77-88.
    PubMed     Text format     Abstract available


  12. SABA NF, Blumenschein G Jr, Guigay J, Licitra L, et al
    Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.
    Oral Oncol. 2019;96:7-14.
    PubMed     Text format     Abstract available


  13. MOON JH, Rho YS, Lee SH, Koo BS, et al
    Role of integrin beta1 as a biomarker of stemness in head and neck squamous cell carcinoma.
    Oral Oncol. 2019;96:34-41.
    PubMed     Text format     Abstract available


  14. CHUNG CS, Lo WC, Chen KC, Lin CL, et al
    Clinical benefits from endoscopy screening of esophageal second primary tumor for head and neck cancer patients: Analysis of a hospital-based registry.
    Oral Oncol. 2019;96:27-33.
    PubMed     Text format     Abstract available


  15. DEGRAAFF LH, Platek AJ, Iovoli AJ, Wooten KE, et al
    The effect of time between diagnosis and initiation of treatment on outcomes in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2019;96:148-152.
    PubMed     Text format     Abstract available


  16. FADEN DL, Ding F, Lin Y, Zhai S, et al
    APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
    Oral Oncol. 2019;96:140-147.
    PubMed     Text format     Abstract available


  17. YANG LL, Mao L, Wu H, Chen L, et al
    pDC depletion induced by CD317 blockade drives the antitumor immune response in head and neck squamous cell carcinoma.
    Oral Oncol. 2019;96:131-139.
    PubMed     Text format     Abstract available


  18. YAP T, Seers C, Koo K, Cheng L, et al
    Non-invasive screening of a microRNA-based dysregulation signature in oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2019;96:113-120.
    PubMed     Text format     Abstract available


  19. HAM JC, van Herpen CML, Driessen CML, van der Graaf WTA, et al
    Health-related quality of life of patients treated with chemoradiotherapy plus or minus prophylactic antibiotics to reduce the number of pneumonias for locally advanced head and neck cancer, the PANTAP study.
    Oral Oncol. 2019;96:105-112.
    PubMed     Text format     Abstract available


    August 2019
  20. JAYARAJ R, Madhav MR, Sabarimurugan S, Kumarasamy C, et al
    Key approaches to interpret the findings of a meta-analysis on role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery.
    Oral Oncol. 2019 Aug 30. pii: S1368-8375(19)30296.
    PubMed     Text format    


  21. VISHAL RAO US, Shetty SS, Kudpaje A, Rao GA, et al
    (i) TNM staging for head and neck cancers.
    Oral Oncol. 2019 Aug 27. pii: S1368-8375(19)30292.
    PubMed     Text format    


  22. HADDAD R, Guigay J, Keilholz U, Clement PM, et al
    Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
    Oral Oncol. 2019;97:82-91.
    PubMed     Text format     Abstract available


  23. SHARMA M, Radhakrishnan R
    A two-way relationship between the head and neck cancer and esophageal cancer.
    Oral Oncol. 2019 Aug 20. pii: S1368-8375(19)30290.
    PubMed     Text format    


  24. GIULIANI J, Bonetti A
    Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level.
    Oral Oncol. 2019 Aug 17. pii: S1368-8375(19)30286.
    PubMed     Text format    


  25. FAKURNEJAD S, van Keulen S, Nishio N, Engelen M, et al
    Fluorescence molecular imaging for identification of high-grade dysplasia in patients with head and neck cancer.
    Oral Oncol. 2019;97:50-55.
    PubMed     Text format     Abstract available


  26. ZHU J, Duan B, Shi H, Li Y, et al
    Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2019;97:37-43.
    PubMed     Text format     Abstract available


  27. SUN XS, Lin C, Liang YJ, Chen QY, et al
    Role of zoledronic acid in nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis.
    Oral Oncol. 2019;97:31-36.
    PubMed     Text format     Abstract available


  28. JUNG AR, Roh JL, Kim JS, Choi SH, et al
    Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer.
    Oral Oncol. 2019;95:95-99.
    PubMed     Text format     Abstract available


  29. DONG Y, Ridge JA, Ebersole B, Li T, et al
    Incidence and outcomes of radiation-induced late cranial neuropathy in 10-year survivors of head and neck cancer.
    Oral Oncol. 2019;95:59-64.
    PubMed     Text format     Abstract available


  30. LEONARD BC, Lee ED, Bhola NE, Li H, et al
    ATR inhibition sensitizes HPV(-) and HPV(+) head and neck squamous cell carcinoma to cisplatin.
    Oral Oncol. 2019;95:35-42.
    PubMed     Text format     Abstract available


  31. BLAKAJ A, Bonomi M, Gamez ME, Blakaj DM, et al
    Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data.
    Oral Oncol. 2019;95:29-34.
    PubMed     Text format     Abstract available


  32. CHEN YF, Chang KW, Yang IT, Tu HF, et al
    Establishment of syngeneic murine model for oral cancer therapy.
    Oral Oncol. 2019;95:194-201.
    PubMed     Text format     Abstract available


  33. MADY LJ, Lyu L, Owoc MS, Peddada SD, et al
    Understanding financial toxicity in head and neck cancer survivors.
    Oral Oncol. 2019;95:187-193.
    PubMed     Text format     Abstract available


  34. ZHAI TT, Langendijk JA, van Dijk LV, Halmos GB, et al
    The prognostic value of CT-based image-biomarkers for head and neck cancer patients treated with definitive (chemo-)radiation.
    Oral Oncol. 2019;95:178-186.
    PubMed     Text format     Abstract available


  35. GAU M, Karabajakian A, Reverdy T, Neidhardt EM, et al
    Induction chemotherapy in head and neck cancers: Results and controversies.
    Oral Oncol. 2019;95:164-169.
    PubMed     Text format     Abstract available


  36. ZHANG Y, Zhang ZC, Li WF, Liu X, et al
    Prognosis and staging of parotid lymph node metastasis in nasopharyngeal carcinoma: An analysis in 10,126 patients.
    Oral Oncol. 2019;95:150-156.
    PubMed     Text format     Abstract available


  37. PARK SJ, Ye W, Xiao R, Silvin C, et al
    Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
    Oral Oncol. 2019;95:127-135.
    PubMed     Text format     Abstract available


  38. BARBOSA DA SILVA JL, Doty RL, Miyazaki JVMK, Borges R, et al
    Gustatory disturbances occur in patients with head and neck cancer who undergo radiotherapy not directed to the oral cavity.
    Oral Oncol. 2019;95:115-119.
    PubMed     Text format     Abstract available


  39. DAUZIER E, Lacas B, Blanchard P, Le QT, et al
    Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer.
    Oral Oncol. 2019;95:106-114.
    PubMed     Text format     Abstract available


  40. SALUJA TS, Iyer J, Singh SK
    Leiomyosarcoma: Prognostic outline of a rare head and neck malignancy.
    Oral Oncol. 2019;95:100-105.
    PubMed     Text format     Abstract available


  41. ARGYRIS PP, Slama Z, Malz C, Koutlas IG, et al
    Intracellular calprotectin (S100A8/A9) controls epithelial differentiation and caspase-mediated cleavage of EGFR in head and neck squamous cell carcinoma.
    Oral Oncol. 2019;95:1-10.
    PubMed     Text format     Abstract available


  42. LAURITANO D, Oberti L, Gabrione F, Lucchese A, et al
    Liquid biopsy in head and neck squamous cell carcinoma: Prognostic significance of circulating tumor cells and circulating tumor DNA. A systematic review.
    Oral Oncol. 2019;97:7-17.
    PubMed     Text format    


    July 2019
  43. SHI L, Wang Y, Li C, Liu W, et al
    Current evidence on DNA aneuploidy cytology in noninvasive detection of oral cancer.
    Oral Oncol. 2019 Jul 9. pii: S1368-8375(19)30244.
    PubMed     Text format     Abstract available


  44. KOKKALI S, Ntokou A, Drizou M, Perdikari K, et al
    Nivolumab in patients with rare head and neck carcinomas: A single center's experience.
    Oral Oncol. 2019 Jul 9. pii: S1368-8375(19)30237.
    PubMed     Text format     Abstract available


  45. SUROV A, Meyer HJ, Hohn AK, Wienke A, et al
    Combined parameter SUVmax/ADCmean predicts microvessel density in head and neck squamous cell carcinoma. Preliminary results.
    Oral Oncol. 2019 Jul 3. pii: S1368-8375(19)30227.
    PubMed     Text format    


  46. ECONOMOPOULOU P, Koutsodontis G, Strati A, Kirodimos E, et al
    Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC).
    Oral Oncol. 2019;94:93-100.
    PubMed     Text format     Abstract available


  47. CHEN X, Liang W, Wan N, Zhang L, et al
    Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2019;94:80-85.
    PubMed     Text format     Abstract available


  48. SUN XS, Liang YJ, Liu SL, Li XY, et al
    Establishment and validation of a nomogram for predicting survival in patients with de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2019;94:73-79.
    PubMed     Text format     Abstract available


  49. DEN TOOM IJ, Boeve K, van Weert S, Bloemena E, et al
    High rate of unexpected lymphatic drainage patterns and a high accuracy of the sentinel lymph node biopsy in oral cancer after previous neck treatment.
    Oral Oncol. 2019;94:68-72.
    PubMed     Text format     Abstract available


  50. DI CREDICO G, Edefonti V, Polesel J, Pauli F, et al
    Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach.
    Oral Oncol. 2019;94:47-57.
    PubMed     Text format     Abstract available


  51. BENCHETRIT L, Torabi SJ, Tate JP, Mehra S, et al
    Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment.
    Oral Oncol. 2019;94:32-40.
    PubMed     Text format     Abstract available


  52. CHOI WR, Roh JL, Gong G, Cho KJ, et al
    Multifocality of papillary thyroid carcinoma as a risk factor for disease recurrence.
    Oral Oncol. 2019;94:106-110.
    PubMed     Text format     Abstract available


  53. ROHDE M, Nielsen AL, Johansen J, Sorensen JA, et al
    Upfront PET/CT affects management decisions in patients with recurrent head and neck squamous cell carcinoma.
    Oral Oncol. 2019;94:1-7.
    PubMed     Text format     Abstract available


    June 2019
  54. CHARGI N, Ansari E, Huiskamp LFJ, Bol G, et al
    Agreement between skeletal muscle mass measurements using computed tomography imaging and magnetic resonance imaging in head and neck cancer patients.
    Oral Oncol. 2019 Jun 25. pii: S1368-8375(19)30211.
    PubMed     Text format    


  55. CHEN JJ, Harris JP, Kong CS, Sunwoo JB, et al
    Corrigendum to 'Clinical perineural invasion of cutaneous head and neck cancer: Impact of radiotherapy, imaging, and nerve growth factor receptors on symptom control and prognosis'. [Oral Oncol. 85 (2018) 60-67].
    Oral Oncol. 2019 Jun 4. pii: S1368-8375(19)30171.
    PubMed     Text format    


  56. MCMULLEN CP, Garneau J, Weimar E, Ali S, et al
    Occult contralateral nodal disease in oropharyngeal squamous cell carcinoma patients undergoing primary TORS with bilateral neck dissection.
    Oral Oncol. 2019;93:96-100.
    PubMed     Text format     Abstract available


  57. CAO C, Yang P, Xu Y, Niu T, et al
    Feasibility of multiparametric imaging with PET/MR in nasopharyngeal carcinoma: A pilot study.
    Oral Oncol. 2019;93:91-95.
    PubMed     Text format     Abstract available


  58. TROIANO G, Caponio VCA, Adipietro I, Tepedino M, et al
    Prognostic significance of CD68(+) and CD163(+) tumor associated macrophages in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2019;93:66-75.
    PubMed     Text format     Abstract available


  59. RAMBEAU A, Bastit V, Thureau S, Thariat J, et al
    Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2019;93:46-51.
    PubMed     Text format     Abstract available


  60. LIAO W, Huang J, Wu Q, Zhu G, et al
    Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Oral Oncol. 2019;93:15-20.
    PubMed     Text format     Abstract available


  61. FUJII T, Miyabe J, Yoshii T, Suzuki M, et al
    Metabolic tumor volume of metastatic lymph nodes and survival after total laryngectomy in laryngeal and hypopharyngeal cancer.
    Oral Oncol. 2019;93:107-113.
    PubMed     Text format     Abstract available


  62. CHEN X, Zheng Y, Tatsuoka C, Muzic RF Jr, et al
    Chemoradiotherapy-related carotid artery inflammation in head and neck cancer patients quantified by [(18)F]FDG PET/CT.
    Oral Oncol. 2019;93:101-106.
    PubMed     Text format     Abstract available


  63. BONOMO P, Greto D, Desideri I, Loi M, et al
    Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?
    Oral Oncol. 2019;93:1-7.
    PubMed     Text format     Abstract available


    May 2019
  64. BOSSI P, Seront E, Machiels JP
    May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?
    Oral Oncol. 2019 May 21. pii: S1368-8375(19)30158.
    PubMed     Text format    


  65. FERNANDEZ-FEIJOO J, Fernandez-Varela M, Diniz-Freitas M, Diz-Dios P, et al
    Why refer possible oral cancer to the dentist for assessment?
    Oral Oncol. 2019 May 14. pii: S1368-8375(19)30153.
    PubMed     Text format    


  66. ABRAM TJ, Floriano PN, James R, Kerr AR, et al
    Development of a cytology-based multivariate analytical risk index for oral cancer.
    Oral Oncol. 2019;92:6-11.
    PubMed     Text format     Abstract available


  67. LIANG YJ, Sun XS, Yang ZC, Tang QN, et al
    Effect of local treatment for metastasis and its sequence with chemotherapy on prognosis of post-treatment metastatic nasopharyngeal carcinoma patients.
    Oral Oncol. 2019;92:40-45.
    PubMed     Text format     Abstract available


  68. GREENE S, Patel P, Allen CT
    How patients with an intact immune system develop head and neck cancer.
    Oral Oncol. 2019;92:26-32.
    PubMed     Text format     Abstract available


  69. SUNNY SP, Agarwal S, James BL, Heidari E, et al
    Intra-operative point-of-procedure delineation of oral cancer margins using optical coherence tomography.
    Oral Oncol. 2019;92:12-19.
    PubMed     Text format     Abstract available


  70. SMITH WH, Luskin I, Resende Salgado L, Scarborough BM, et al
    Risk of prolonged opioid use among cancer patients undergoing curative intent radiation therapy for head and neck malignancies.
    Oral Oncol. 2019;92:1-5.
    PubMed     Text format     Abstract available


    April 2019
  71. HARTMAN DJ, Ahmad FS, Ferris RL, Rimm DL, et al
    Corrigendum to "Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma" [Oral Oncol. 86 (2018) 278-287].
    Oral Oncol. 2019 Apr 30. pii: S1368-8375(19)30128.
    PubMed     Text format    


  72. DE FELICE F, Polimeni A, Tombolini V
    Human papillomavirus (HPV) vaccine and HPV-related head and neck cancer: What's next?
    Oral Oncol. 2019 Apr 4. pii: S1368-8375(19)30101.
    PubMed     Text format    


  73. CHAN JYW, Wong STS, Wei WI
    Surgical salvage of recurrent T3 nasopharyngeal carcinoma: Prognostic significance of clivus, maxillary, temporal and sphenoid bone invasion.
    Oral Oncol. 2019;91:85-91.
    PubMed     Text format     Abstract available


  74. LUO WJ, Feng YF, Guo R, Tang LL, et al
    Patterns of EBV-positive cervical lymph node involvement in head and neck cancer and implications for the management of nasopharyngeal carcinoma T0 classification.
    Oral Oncol. 2019;91:7-12.
    PubMed     Text format     Abstract available


  75. EZE N, Lee JW, Yang DH, Zhu F, et al
    PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2019;91:69-78.
    PubMed     Text format     Abstract available


  76. TSAI MS, Chen WC, Lu CH, Chen MF, et al
    The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
    Oral Oncol. 2019;91:47-55.
    PubMed     Text format     Abstract available


  77. GUY JB, Benna M, Xia Y, Daguenet E, et al
    Quality insurance in head and neck cancer multidisciplinary team meetings: A watchful eye on real-life experience.
    Oral Oncol. 2019;91:35-38.
    PubMed     Text format     Abstract available


  78. SONG E, Ahn J, Oh HS, Jeon MJ, et al
    Time trends of thyroglobulin antibody in ablated papillary thyroid carcinoma patients: Can we predict the rate of negative conversion?
    Oral Oncol. 2019;91:29-34.
    PubMed     Text format     Abstract available


  79. GUO Q, Lu T, Hui Huang S, O'Sullivan B, et al
    Depicting distant metastatic risk by refined subgroups derived from the 8th edition nasopharyngeal carcinoma TNM.
    Oral Oncol. 2019;91:113-120.
    PubMed     Text format     Abstract available


    March 2019
  80. DE BREE R, Takes RP, Shah JP, Hamoir M, et al
    Elective neck dissection in oral squamous cell carcinoma: Past, present and future.
    Oral Oncol. 2019;90:87-93.
    PubMed     Text format     Abstract available


  81. EL-SALEM F, Mansour M, Gitman M, Miles BA, et al
    Real-time PCR HPV genotyping in fine needle aspirations of metastatic head and neck squamous cell carcinoma: Exposing the limitations of conventional p16 immunostaining.
    Oral Oncol. 2019;90:74-79.
    PubMed     Text format     Abstract available


  82. GHANIZADA M, Jakobsen KK, Gronhoj C, von Buchwald C, et al
    The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2019;90:67-73.
    PubMed     Text format     Abstract available


  83. KANG S
    Organ preservation in laryngeal and hypopharyngeal cancer.
    Oral Oncol. 2019;90:6-7.
    PubMed     Text format    


  84. GUPTA A, Stokes W, Eguchi M, Hararah M, et al
    Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer.
    Oral Oncol. 2019;90:54-66.
    PubMed     Text format     Abstract available


  85. YUNG CS, Leung DKC, Cheung JPY
    The prevalence and impact of cervical spine pathologies in patients with nasopharyngeal carcinoma.
    Oral Oncol. 2019;90:48-53.
    PubMed     Text format     Abstract available


  86. FRIEDMAN J, Padget M, Lee J, Schlom J, et al
    Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
    Oral Oncol. 2019;90:38-44.
    PubMed     Text format     Abstract available


  87. WANG YQ, Lv JW, Tang LL, Du XJ, et al
    Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual.
    Oral Oncol. 2019;90:23-29.
    PubMed     Text format     Abstract available


  88. LIU J, Zhang Z, Huang H, Xu S, et al
    Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis.
    Oral Oncol. 2019;90:17-22.
    PubMed     Text format     Abstract available


  89. GARCIA GCTE, Gorphe P, Hartl D, Ammari S, et al
    Computed tomography evaluation after induction chemotherapy for T3 laryngeal cancer: Does response correlate with vocal cord mobility?
    Oral Oncol. 2019;90:13-16.
    PubMed     Text format     Abstract available


  90. BADR H, Sobrero M, Chen J, Kotz T, et al
    Associations between pre-, post-, and peri-operative variables and health resource use following surgery for head and neck cancer.
    Oral Oncol. 2019;90:102-108.
    PubMed     Text format     Abstract available


  91. MIAO J, Wang L, Zhu M, Xiao W, et al
    Corrigendum to "Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy" [Oral Oncol. 89 (2019)
    Oral Oncol. 2019;90:136.
    PubMed     Text format    


  92. MIAO J, Wang L, Zhu M, Xiao W, et al
    Reprint of Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy.
    Oral Oncol. 2019;90:126-133.
    PubMed     Text format     Abstract available


    February 2019
  93. SALEH K, Saada E, Auger N, Mayache-Badis L, et al
    Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck.
    Oral Oncol. 2019 Feb 14. pii: S1368-8375(19)30044.
    PubMed     Text format    


  94. YU ST, Xiao ZZ
    Letter to the Editor regarding, "Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis".
    Oral Oncol. 2019 Feb 14. pii: S1368-8375(19)30045.
    PubMed     Text format    


  95. GAUBATZ ME, Bukatko AR, Simpson MC, Polednik KM, et al
    Racial and socioeconomic disparities associated with 90-day mortality among patients with head and neck cancer in the United States.
    Oral Oncol. 2019;89:95-101.
    PubMed     Text format     Abstract available


  96. CHUNG EJ, Jeong WJ, Jung YH, Kwon SK, et al
    Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases.
    Oral Oncol. 2019;89:84-94.
    PubMed     Text format     Abstract available


  97. NAM KIM Y, Kim M, Seon Ahn H, Kim K, et al
    Refining the tumor-node-metastasis staging system for individualized treatment of differentiated thyroid carcinoma.
    Oral Oncol. 2019;89:8-13.
    PubMed     Text format     Abstract available


  98. TEFT WA, Winquist E, Nichols AC, Kuruvilla S, et al
    Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients.
    Oral Oncol. 2019;89:72-78.
    PubMed     Text format     Abstract available


  99. HUANG CC, Lin CN, Chung CH, Hwang JS, et al
    Cost-effectiveness analysis of the oral cancer screening program in Taiwan.
    Oral Oncol. 2019;89:59-65.
    PubMed     Text format     Abstract available


  100. JACOBS CD, Barbour AB, Mowery YM
    The relative distribution of oral cancer in the United States by subsite.
    Oral Oncol. 2019;89:56-58.
    PubMed     Text format    


  101. SIMPSON MC, Challapalli SD, Cass LM, Zahirsha ZS, et al
    Impact of gender on the association between marital status and head and neck cancer outcomes.
    Oral Oncol. 2019;89:48-55.
    PubMed     Text format     Abstract available


  102. MIAO J, Wang L, Zhu M, Xiao W, et al
    Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy.
    Oral Oncol. 2019;89:40-47.
    PubMed     Text format    


  103. CHIKAMATSU K, Tada H, Takahashi H, Kuwabara-Yokobori Y, et al
    Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2019;89:34-39.
    PubMed     Text format     Abstract available


  104. HEALY CM, Moran GP
    The microbiome and oral cancer: More questions than answers.
    Oral Oncol. 2019;89:30-33.
    PubMed     Text format     Abstract available


  105. FARQUHAR DR, Masood MM, Lenze NR, McDaniel P, et al
    Travel time to provider is associated with advanced stage at diagnosis among low income head and neck squamous cell carcinoma patients in North Carolina.
    Oral Oncol. 2019;89:115-120.
    PubMed     Text format     Abstract available


  106. PENG L, Xu C, Chen YP, Guo R, et al
    Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort.
    Oral Oncol. 2019;89:102-106.
    PubMed     Text format     Abstract available


    January 2019
  107. JAYARAJ R, Kumarasamy C
    Conceptual interpretation of analysing and reporting of results on systematic review and meta-analysis of optimal extent of lateral neck dissection for well-differentiated thyroid carcinoma with metastatic lateral neck lymph nodes.
    Oral Oncol. 2019 Jan 3. pii: S1368-8375(18)30497.
    PubMed     Text format    


  108. FOY JP, Bertolus C, Saintigny P
    Oral cancer prevention worldwide: Challenges and perspectives.
    Oral Oncol. 2019;88:91-94.
    PubMed     Text format    


  109. HAQUE S, Karivedu V, Riaz MK, Choi D, et al
    High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2019;88:9-15.
    PubMed     Text format     Abstract available


  110. MAY ME JR, Cash ED, Silverman CL, Redman RA, et al
    Prognostic factors and selection criteria in the retreatment of head and neck cancers.
    Oral Oncol. 2019;88:85-90.
    PubMed     Text format     Abstract available


  111. ALTAMURA G, Borzacchiello G
    HPV related head and neck squamous cell carcinoma: New evidences for an emerging spontaneous animal model.
    Oral Oncol. 2019;88:84.
    PubMed     Text format    


  112. MARTENS RM, Noij DP, Ali M, Koopman T, et al
    Functional imaging early during (chemo)radiotherapy for response prediction in head and neck squamous cell carcinoma; a systematic review.
    Oral Oncol. 2019;88:75-83.
    PubMed     Text format     Abstract available


  113. MORENO AC, Frank SJ, Garden AS, Rosenthal DI, et al
    Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer.
    Oral Oncol. 2019;88:66-74.
    PubMed     Text format     Abstract available


  114. GREGOIRE V, Ng WT
    Special section on intensity-modulated radiation therapy for head and neck cancer (IMRT).
    Oral Oncol. 2019;88:49-50.
    PubMed     Text format    


  115. GOEL AN, Frangos MI, Raghavan G, Lazaro SL, et al
    The impact of treatment package time on survival in surgically managed head and neck cancer in the United States.
    Oral Oncol. 2019;88:39-48.
    PubMed     Text format     Abstract available


  116. EVRARD D, Szturz P, Tijeras-Raballand A, Astorgues-Xerri L, et al
    Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.
    Oral Oncol. 2019;88:29-38.
    PubMed     Text format     Abstract available


  117. SHETTY SS, Vishal Rao US
    8 "S" in oral cancer.
    Oral Oncol. 2019;88:27-28.
    PubMed     Text format    


  118. KARSTEN RT, Stuiver MM, van der Molen L, Navran A, et al
    From reactive to proactive tube feeding during chemoradiotherapy for head and neck cancer: A clinical prediction model-based approach.
    Oral Oncol. 2019;88:172-179.
    PubMed     Text format     Abstract available


  119. LIU JC, Bhayani M, Kuchta K, Galloway T, et al
    Patterns of distant metastasis in head and neck cancer at presentation: Implications for initial evaluation.
    Oral Oncol. 2019;88:131-136.
    PubMed     Text format     Abstract available


  120. KIM Y, Roh JL, Kim JS, Lee JH, et al
    Chest radiography or chest CT plus head and neck CT versus (18)F-FDG PET/CT for detection of distant metastasis and synchronous cancer in patients with head and neck cancer.
    Oral Oncol. 2019;88:109-114.
    PubMed     Text format     Abstract available


  121. FENG RM, Chang ET, Liu Z, Liu Q, et al
    Reproductive history and risk of nasopharyngeal carcinoma: A population-based case-control study in southern China.
    Oral Oncol. 2019;88:102-108.
    PubMed     Text format     Abstract available


    December 2018
  122. JAYARAJ R, Kumarasamy C
    Letter to the Editor about the Article: "Performance of different imaging techniques in the diagnosis of head and neck cancer mandibular invasion: A systematic review and meta-analysis".
    Oral Oncol. 2018 Dec 31. pii: S1368-8375(18)30490.
    PubMed     Text format    


  123. JAYARAJ R, Kumarasamy C, Samiappan S, Swaminathan P, et al
    Letter to the Editor regarding, "The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis".
    Oral Oncol. 2018 Dec 19. pii: S1368-8375(18)30482.
    PubMed     Text format    


  124. DENG L, Cao Y, Lin J
    Regional recurrence rate of lymph-node-positive thyroid carcinoma after selective or comprehensive neck dissection.
    Oral Oncol. 2018 Dec 13. pii: S1368-8375(18)30456.
    PubMed     Text format    


  125. KIM M, Kim HI, Jeon MJ, Kim HK, et al
    Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study.
    Oral Oncol. 2018;87:97-103.
    PubMed     Text format     Abstract available


  126. BAIRD BJ, Sung CK, Beadle BM, Divi V, et al
    Treatment of early-stage laryngeal cancer: A comparison of treatment options.
    Oral Oncol. 2018;87:8-16.
    PubMed     Text format     Abstract available


  127. MCCLELLAND S 3RD, Andrews JZ, Chaudhry H, Teckie S, et al
    Prophylactic versus reactive gastrostomy tube placement in advanced head and neck cancer treated with definitive chemoradiotherapy: A systematic review.
    Oral Oncol. 2018;87:77-81.
    PubMed     Text format     Abstract available


  128. D'CRUZ AK, Vaish R, Dhar H
    Oral cancers: Current status.
    Oral Oncol. 2018;87:64-69.
    PubMed     Text format     Abstract available


  129. CHUANG SL, Wang CP, Chen MK, Su WW, et al
    Malignant transformation to oral cancer by subtype of oral potentially malignant disorder: A prospective cohort study of Taiwanese nationwide oral cancer screening program.
    Oral Oncol. 2018;87:58-63.
    PubMed     Text format     Abstract available


  130. TANAKA N, Osman AA, Takahashi Y, Lindemann A, et al
    Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Oral Oncol. 2018;87:49-57.
    PubMed     Text format     Abstract available


  131. DUA B, Chufal KS, Bhatnagar A, Thakwani A, et al
    Nodal volume as a prognostic factor in locally advanced head and neck cancer: Identifying candidates for elective neck dissection after chemoradiation with IGRT from a single institutional prospective series from the Indian subcontinent.
    Oral Oncol. 2018;87:179-185.
    PubMed     Text format     Abstract available


  132. OLATUNJI I
    Potential application of tumor suppressor microRNAs for targeted therapy in head and neck cancer: A mini-review.
    Oral Oncol. 2018;87:165-169.
    PubMed     Text format     Abstract available


  133. NAM SH, Bae MR, Roh JL, Gong G, et al
    A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.
    Oral Oncol. 2018;87:158-164.
    PubMed     Text format     Abstract available


  134. RANGEL JB, Thuler LCS, Pinto JFDC
    Prevalence of hepatitis C virus infection and its impact on the prognosis of head and neck cancer patients.
    Oral Oncol. 2018;87:138-143.
    PubMed     Text format     Abstract available


  135. WON HR, Chang JW, Kang YE, Kang JY, et al
    Optimal extent of lateral neck dissection for well-differentiated thyroid carcinoma with metastatic lateral neck lymph nodes: A systematic review and meta-analysis.
    Oral Oncol. 2018;87:117-125.
    PubMed     Text format     Abstract available


  136. KEARNEY V, Chan JW, Valdes G, Solberg TD, et al
    The application of artificial intelligence in the IMRT planning process for head and neck cancer.
    Oral Oncol. 2018;87:111-116.
    PubMed     Text format     Abstract available


  137. HIRSCHMANN A, Lupatsch JE, Schwenkglenks M, Panje CM, et al
    Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
    Oral Oncol. 2018;87:104-110.
    PubMed     Text format     Abstract available


    November 2018
  138. HUANG NS, Wei WJ, Qu N, Wang YL, et al
    Lingual ectopic papillary thyroid carcinoma: Two case reports and review of the literature.
    Oral Oncol. 2018 Nov 22. pii: S1368-8375(18)30428.
    PubMed     Text format     Abstract available


  139. LIU W, Chen S, Yang W
    The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma.
    Oral Oncol. 2018 Nov 2. pii: S1368-8375(18)30404.
    PubMed     Text format    


  140. ANDREASSEN CN, Eriksen JG, Jensen K, Hansen CR, et al
    IMRT - Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer.
    Oral Oncol. 2018;86:91-99.
    PubMed     Text format     Abstract available


  141. YANG WF, Wong MCM, Thomson PJ, Li KY, et al
    The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2018;86:81-90.
    PubMed     Text format     Abstract available


  142. KIM M, Kim HK, Kim HI, Kim EH, et al
    Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: A multi-institutional cohort study.
    Oral Oncol. 2018;86:48-52.
    PubMed     Text format     Abstract available


  143. BONOMI MR, Blakaj A, Blakaj D
    Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies.
    Oral Oncol. 2018;86:301-306.
    PubMed     Text format     Abstract available


  144. EVANS M, Beasley M
    Target delineation for postoperative treatment of head and neck cancer.
    Oral Oncol. 2018;86:288-295.
    PubMed     Text format     Abstract available


  145. HARTMAN DJ, Ahmad F, Ferris RL, Rimm DL, et al
    Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;86:278-287.
    PubMed     Text format     Abstract available


  146. PENG L, Chen YP, Xu C, Tang LL, et al
    A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.
    Oral Oncol. 2018;86:258-265.
    PubMed     Text format     Abstract available


  147. FUJIWARA T, Eguchi T, Sogawa C, Ono K, et al
    Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab.
    Oral Oncol. 2018;86:251-257.
    PubMed     Text format     Abstract available


  148. SEGRELLES C, Paramio JM, Lorz C
    The transcriptional co-activator YAP: A new player in head and neck cancer.
    Oral Oncol. 2018;86:25-32.
    PubMed     Text format     Abstract available


  149. GARNEAU JC, Bakst RL, Miles BA
    Hypopharyngeal cancer: A state of the art review.
    Oral Oncol. 2018;86:244-250.
    PubMed     Text format     Abstract available


  150. KASHYAP T, Pramanik KK, Nath N, Mishra P, et al
    Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3beta signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
    Oral Oncol. 2018;86:234-243.
    PubMed     Text format     Abstract available


  151. GUJRAL DM, Nutting CM
    Patterns of failure, treatment outcomes and late toxicities of head and neck cancer in the current era of IMRT.
    Oral Oncol. 2018;86:225-233.
    PubMed     Text format     Abstract available


  152. SPECTOR ME, Rosko AJ, Swiecicki PL, Chad Brenner J, et al
    From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer.
    Oral Oncol. 2018;86:200-205.
    PubMed     Text format     Abstract available


  153. ESKANDER A, Blakaj DM, Dziegielewski PT
    Decision making in advanced larynx cancer: An evidenced based review.
    Oral Oncol. 2018;86:195-199.
    PubMed     Text format     Abstract available


  154. GENSHEIMER MF, Le QT
    Adaptive radiotherapy for head and neck cancer: Are we ready to put it into routine clinical practice?
    Oral Oncol. 2018;86:19-24.
    PubMed     Text format     Abstract available


  155. QIAO X, Liu W, Cao Y, Miao C, et al
    Performance of different imaging techniques in the diagnosis of head and neck cancer mandibular invasion: A systematic review and meta-analysis.
    Oral Oncol. 2018;86:150-164.
    PubMed     Text format     Abstract available


  156. CHUANG HC, Chou MH, Chien CY, Chuang JH, et al
    Triggering TLR3 pathway promotes tumor growth and cisplatin resistance in head and neck cancer cells.
    Oral Oncol. 2018;86:141-149.
    PubMed     Text format     Abstract available


  157. ZANDBERG DP, Cullen K, Bentzen SM, Goloubeva OG, et al
    Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
    Oral Oncol. 2018;86:132-140.
    PubMed     Text format     Abstract available


  158. SHAIKH MH, Idris A, Johnson NW, Fallaha S, et al
    Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.
    Oral Oncol. 2018;86:105-112.
    PubMed     Text format     Abstract available


  159. DO JH, Yoon IJ, Cho YK, Ahn JS, et al
    Comparison of hospital based and home based exercise on quality of life, and neck and shoulder function in patients with spinal accessary nerve injury after head and neck cancer surgery.
    Oral Oncol. 2018;86:100-104.
    PubMed     Text format     Abstract available


    October 2018
  160. CAPPELLI E, Degan P, Dufour C, Ravera S, et al
    Aerobic metabolism dysfunction as one of the links between Fanconi anemia-deficient pathway and the aggressive cell invasion in head and neck cancer cells.
    Oral Oncol. 2018 Oct 20. pii: S1368-8375(18)30370.
    PubMed     Text format    


  161. SHETTY SS, Vishal Rao US
    Changing sexual practices: A possible link to oral cancer.
    Oral Oncol. 2018 Oct 10. pii: S1368-8375(18)30356.
    PubMed     Text format    


  162. LI PJ, Mo HY, Luo DH, Hu WH, et al
    The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Oral Oncol. 2018;85:95-100.
    PubMed     Text format     Abstract available


  163. AMBATIPUDI S, Langdon R, Richmond RC, Suderman M, et al
    DNA methylation derived systemic inflammation indices are associated with head and neck cancer development and survival.
    Oral Oncol. 2018;85:87-94.
    PubMed     Text format     Abstract available


  164. LU L, Sheng Y, Zhang G, Li Y, et al
    Temporal lobe injury patterns following intensity modulated radiotherapy in a large cohort of nasopharyngeal carcinoma patients.
    Oral Oncol. 2018;85:8-14.
    PubMed     Text format     Abstract available


  165. SAKA HERRAN C, Jane-Salas E, Estrugo Devesa A, Lopez-Lopez J, et al
    Protective effects of metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic review.
    Oral Oncol. 2018;85:68-81.
    PubMed     Text format     Abstract available


  166. CHEN JJ, Harris JP, Kong CS, Sunwoo JB, et al
    Clinical perineural invasion of cutaneous head and neck cancer: Impact of radiotherapy, imaging, and nerve growth factor receptors on symptom control and prognosis.
    Oral Oncol. 2018;85:60-67.
    PubMed     Text format     Abstract available


  167. LEE DJ, Eun YG, Rho YS, Kim EH, et al
    Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes.
    Oral Oncol. 2018;85:44-51.
    PubMed     Text format     Abstract available


  168. LIN DJ, McConkey CC, Nankivell P, Dunn J, et al
    The impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of patients with head and neck cancer: An analysis of the PET-NECK trial outcomes, UKCRN portfolio, and Hospital Episode Statistics (HES) in England.
    Oral Oncol. 2018;85:40-43.
    PubMed     Text format     Abstract available


  169. SRIDHARAN V, Rahman RM, Huang RY, Chau NG, et al
    Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2018;85:29-34.
    PubMed     Text format     Abstract available


    September 2018
  170. MORAND GB, Helmchen BM, Steinert HC, Schmid C, et al
    18F-Choline-PET in parathyroid carcinoma.
    Oral Oncol. 2018 Sep 28. pii: S1368-8375(18)30324.
    PubMed     Text format    


  171. PANTA P
    'Meditation Training Intervention' - A necessary shift for head and neck cancer patients.
    Oral Oncol. 2018 Sep 8. pii: S1368-8375(18)30316.
    PubMed     Text format    


  172. SALOURA V, Vougiouklakis T, Burkitt K, Nakamura Y, et al
    Corrigendum to "The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck" [Oral Oncol. 81 (2018) 100-108].
    Oral Oncol. 2018 Sep 7. pii: S1368-8375(18)30313.
    PubMed     Text format    


  173. DRONKERS EAC, Hoesseini A, de Boer MF, Offerman MPJ, et al
    Communication of prognosis in head and neck cancer patients; a descriptive qualitative analysis.
    Oral Oncol. 2018;84:76-81.
    PubMed     Text format     Abstract available


  174. CHEN MM, Colevas AD, Megwalu U, Divi V, et al
    Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age.
    Oral Oncol. 2018;84:71-75.
    PubMed     Text format     Abstract available


  175. FARQUHAR DR, Tanner AM, Masood MM, Patel SR, et al
    Oral tongue carcinoma among young patients: An analysis of risk factors and survival.
    Oral Oncol. 2018;84:7-11.
    PubMed     Text format     Abstract available


  176. WEISS J, Gilbert J, Deal AM, Weissler M, et al
    Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
    Oral Oncol. 2018;84:46-51.
    PubMed     Text format     Abstract available


  177. PARK SY, Kim HI, Choi JY, Choe JH, et al
    Low versus high activity radioiodine remnant ablation for differentiated thyroid carcinoma with gross extrathyroidal extension invading only strap muscles.
    Oral Oncol. 2018;84:41-45.
    PubMed     Text format     Abstract available


  178. PENG LC, Hui X, Cheng Z, Bowers MR, et al
    Prospective evaluation of patient reported swallow function with the Functional Assessment of Cancer Therapy (FACT), MD Anderson Dysphagia Inventory (MDADI) and the Sydney Swallow Questionnaire (SSQ) in head and neck cancer patients.
    Oral Oncol. 2018;84:25-30.
    PubMed     Text format     Abstract available


  179. STOKES WA, Eguchi M, Amini A, Hararah MK, et al
    Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset.
    Oral Oncol. 2018;84:12-19.
    PubMed     Text format     Abstract available


  180. LALA M, Chirovsky D, Cheng JD, Mayawala K, et al
    Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
    Oral Oncol. 2018;84:108-120.
    PubMed     Text format     Abstract available


  181. LI Y, Xu T, Qian W, Lu X, et al
    Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
    Oral Oncol. 2018;84:1-6.
    PubMed     Text format     Abstract available


    August 2018
  182. ANGELIDAKIS G, Sturgis EM, Economides MP, Jiang Y, et al
    Chronic hepatitis C virus infection on patients with nonoropharyngeal head and neck cancers.
    Oral Oncol. 2018 Aug 25. pii: S1368-8375(18)30303.
    PubMed     Text format    


  183. PATTERSON JM, McColl E, Carding PN, Wilson JA, et al
    Swallowing beyond six years post (chemo)radiotherapy for head and neck cancer; a cohort study.
    Oral Oncol. 2018;83:53-58.
    PubMed     Text format     Abstract available


  184. CHOI N, Park SI, Kim H, Sohn I, et al
    The impact of unplanned reoperations in head and neck cancer surgery on survival.
    Oral Oncol. 2018;83:38-45.
    PubMed     Text format     Abstract available


  185. LECHNER M, Chakravarthy AR, Walter V, Masterson L, et al
    Frequent HPV-independent p16/INK4A overexpression in head and neck cancer.
    Oral Oncol. 2018;83:32-37.
    PubMed     Text format     Abstract available


  186. MELISSANT HC, Jansen F, Schutte LER, Lissenberg-Witte BI, et al
    The course of sexual interest and enjoyment in head and neck cancer patients treated with primary (chemo)radiotherapy.
    Oral Oncol. 2018;83:120-126.
    PubMed     Text format     Abstract available


  187. HICKS DF, Bakst R, Doucette J, Kann BH, et al
    Impact of obesity on outcomes for patients with head and neck cancer.
    Oral Oncol. 2018;83:11-17.
    PubMed     Text format     Abstract available


  188. ESKANDER A, Krzyzanowska MK, Fischer HD, Liu N, et al
    Emergency department visits and unplanned hospitalizations in the treatment period for head and neck cancer patients treated with curative intent: A population-based analysis.
    Oral Oncol. 2018;83:107-114.
    PubMed     Text format     Abstract available


  189. WILKIE MD, Lau AS, Vlatkovic N, Jones TM, et al
    Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives.
    Oral Oncol. 2018;83:1-10.
    PubMed     Text format     Abstract available


    July 2018
  190. DE BREE R, de Keizer B
    Is there a place for FDG-PET-CT in early oral cancer patients?
    Oral Oncol. 2018 Jul 31. pii: S1368-8375(18)30276.
    PubMed     Text format    


  191. FERRAROTTO R, William WN Jr, Tseng JE, Marur S, et al
    Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2018;82:83-90.
    PubMed     Text format     Abstract available


  192. RETTIG EM, Bishop JA, Agrawal N, Chung CH, et al
    HEY1 is expressed independent of NOTCH1 and is associated with poor prognosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;82:168-175.
    PubMed     Text format     Abstract available


  193. HOROWITZ G, Hosni A, Yu E, Xu W, et al
    Prevalence, prognosis, and treatment implications of retropharyngeal nodes in unknown primary head and neck carcinoma.
    Oral Oncol. 2018;82:162-167.
    PubMed     Text format     Abstract available


  194. SIANO M, Espeli V, Mach N, Bossi P, et al
    Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial.
    Oral Oncol. 2018;82:144-151.
    PubMed     Text format     Abstract available


  195. MASSA ST, Rohde RL, Mckinstry C, Gresham M, et al
    An assessment of patient burdens from head and neck cancer survivorship care.
    Oral Oncol. 2018;82:115-121.
    PubMed     Text format     Abstract available


  196. PENG YL, Chen L, Shen GZ, Li YN, et al
    Interobserver variations in the delineation of target volumes and organs at risk and their impact on dose distribution in intensity-modulated radiation therapy for nasopharyngeal carcinoma.
    Oral Oncol. 2018;82:1-7.
    PubMed     Text format     Abstract available


    June 2018
  197. MAIR MD, Shetty R, Nair D, Mathur Y, et al
    Depth of invasion, size and number of metastatic nodes predicts extracapsular spread in early oral cancers with occult metastases.
    Oral Oncol. 2018;81:95-99.
    PubMed     Text format     Abstract available


  198. YUE Q, Zhang M, Chen Y, Zheng D, et al
    Establishment of prognostic factors in recurrent nasopharyngeal carcinoma patients who received salvage intensity-modulated radiotherapy: A meta-analysis.
    Oral Oncol. 2018;81:81-88.
    PubMed     Text format     Abstract available


  199. MOTT FE, Ferrarotto R, Nguyen T, Phan J, et al
    Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy.
    Oral Oncol. 2018;81:75-80.
    PubMed     Text format     Abstract available


  200. RASMUSSEN JH, Hakansson K, Rasmussen GB, Vogelius IR, et al
    A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients.
    Oral Oncol. 2018;81:52-60.
    PubMed     Text format     Abstract available


  201. FERRIS RL, Blumenschein G Jr, Fayette J, Guigay J, et al
    Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Oral Oncol. 2018;81:45-51.
    PubMed     Text format     Abstract available


  202. OSAZUWA-PETERS N, Arnold LD, Loux TM, Varvares MA, et al
    Factors associated with increased risk of suicide among survivors of head and neck cancer: A population-based analysis.
    Oral Oncol. 2018;81:29-34.
    PubMed     Text format     Abstract available


  203. KRAEIMA J, Dorgelo B, Gulbitti HA, Steenbakkers RJHM, et al
    Multi-modality 3D mandibular resection planning in head and neck cancer using CT and MRI data fusion: A clinical series.
    Oral Oncol. 2018;81:22-28.
    PubMed     Text format     Abstract available


  204. LIN MC, Shueng PW, Chang WK, Mu-Hsin Chang P, et al
    Consensus and clinical recommendations for nutritional intervention for head and neck cancer patients undergoing chemoradiotherapy in Taiwan.
    Oral Oncol. 2018;81:16-21.
    PubMed     Text format     Abstract available


  205. SALOURA V, Vougiouklakis T, Sievers C, Burkitt K, et al
    The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck.
    Oral Oncol. 2018;81:100-108.
    PubMed     Text format     Abstract available


  206. HANNA GJ, Kofman ER, Shazib MA, Woo SB, et al
    Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.
    Oral Oncol. 2018;81:1-9.
    PubMed     Text format     Abstract available


    May 2018
  207. CARPENTER DJ, Mowery YM, Broadwater G, Rodrigues A, et al
    The risk of carotid stenosis in head and neck cancer patients after radiation therapy.
    Oral Oncol. 2018;80:9-15.
    PubMed     Text format     Abstract available


  208. BASHEER HA, Pakanavicius E, Cooper PA, Shnyder SD, et al
    Hypoxia modulates CCR7 expression in head and neck cancers.
    Oral Oncol. 2018;80:64-73.
    PubMed     Text format     Abstract available


  209. NULTON TJ, Kim NK, DiNardo LJ, Morgan IM, et al
    Patients with integrated HPV16 in head and neck cancer show poor survival.
    Oral Oncol. 2018;80:52-55.
    PubMed     Text format     Abstract available


  210. IOCCA O, Farcomeni A, Di Rocco A, Di Maio P, et al
    Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Oral Oncol. 2018;80:40-51.
    PubMed     Text format     Abstract available


  211. HANEMAAIJER SH, van Gijn SE, Oosting SF, Plaat BEC, et al
    Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;80:33-39.
    PubMed     Text format     Abstract available


  212. LIN M, You R, Liu YP, Zhang YN, et al
    Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
    Oral Oncol. 2018;80:1-8.
    PubMed     Text format     Abstract available


    April 2018
  213. TARDY MP, Di Mauro I, Ebran N, Refae S, et al
    Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.
    Oral Oncol. 2018 Apr 6. pii: S1368-8375(18)30124.
    PubMed     Text format    


  214. GARCIA-ESCUDERO R, Segrelles C, Duenas M, Pombo M, et al
    Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
    Oral Oncol. 2018;79:55-63.
    PubMed     Text format     Abstract available


  215. PENG H, Tang LL, Chen BB, Chen L, et al
    Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis.
    Oral Oncol. 2018;79:40-46.
    PubMed     Text format     Abstract available


  216. CAO C, Jiang F, Jin Q, Jin T, et al
    Locoregional extension and patterns of failure for nasopharyngeal carcinoma with intracranial extension.
    Oral Oncol. 2018;79:27-32.
    PubMed     Text format     Abstract available


  217. VAISANEN JA, Alho OP, Koivunen PT, Laara E, et al
    Cause-specific mortality in patients with head and neck cancer: Long-term follow-up of a population-based cohort from 1986 to 2012 accounting for competing risks.
    Oral Oncol. 2018;79:20-26.
    PubMed     Text format     Abstract available


  218. KAMAL M, Ng SP, Eraj SA, Rock CD, et al
    Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer.
    Oral Oncol. 2018;79:1-8.
    PubMed     Text format     Abstract available


    March 2018
  219. GUPTA AA, Pande N, Kheur S, Raj AT, et al
    Assessing the potential role of scaffold-mediated local chemotherapy in oral cancer.
    Oral Oncol. 2018 Mar 16. pii: S1368-8375(18)30111.
    PubMed     Text format    


  220. MIZRACHI A, Migliacci JC, Montero PH, McBride S, et al
    Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution.
    Oral Oncol. 2018;78:94-101.
    PubMed     Text format     Abstract available


  221. HAN MW, Ryu IS, Lee JC, Kim SH, et al
    Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer.
    Oral Oncol. 2018;78:56-63.
    PubMed     Text format     Abstract available


  222. CHAN JYW, Wong STS, Wei WI
    Real time indocyanin green near infrared lymphangiography for the reduction of drainage volume after neck dissection.
    Oral Oncol. 2018;78:52-55.
    PubMed     Text format     Abstract available


  223. XU C, Sun R, Tang LL, Chen L, et al
    Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Oral Oncol. 2018;78:37-45.
    PubMed     Text format     Abstract available


  224. LU S, Concha-Benavente F, Shayan G, Srivastava RM, et al
    STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer.
    Oral Oncol. 2018;78:186-193.
    PubMed     Text format     Abstract available


  225. PARK YP, Jin L, Bennett KB, Wang D, et al
    CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;78:145-150.
    PubMed     Text format     Abstract available


  226. RETZBACH EP, Sheehan SA, Nevel EM, Batra A, et al
    Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target.
    Oral Oncol. 2018;78:126-136.
    PubMed     Text format     Abstract available


  227. BRANDAO NETO JS, Aires FT, Dedivitis RA, Matos LL, et al
    Comparison between magnetic resonance and computed tomography in detecting mandibular invasion in oral cancer: A systematic review and diagnostic meta-analysis: MRI x CT in mandibular invasion.
    Oral Oncol. 2018;78:114-118.
    PubMed     Text format     Abstract available


  228. SLOOTER MD, Handgraaf HJM, Boonstra MC, van der Velden LA, et al
    Detecting tumour-positive resection margins after oral cancer surgery by spraying a fluorescent tracer activated by gamma-glutamyltranspeptidase.
    Oral Oncol. 2018;78:1-7.
    PubMed     Text format     Abstract available


    February 2018
  229. MUMTAZ S, Parrish J, Singh M
    Oculosympathetic paresis after selective neck dissection: A 'distant' complication.
    Oral Oncol. 2018 Feb 16. pii: S1368-8375(18)30042.
    PubMed     Text format    


  230. GOPINATH D, Menon RK
    Comments on "Compositional and functional variations of oral microbiota associated with the mutational changes in oral cancer" by Yang et al.
    Oral Oncol. 2018 Feb 10. pii: S1368-8375(18)30052.
    PubMed     Text format    


  231. PAI SI, Jack Lee J, Carey TE, Westra WH, et al
    HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
    Oral Oncol. 2018;77:92-97.
    PubMed     Text format     Abstract available


  232. GIPSON BJ, Robbins HA, Fakhry C, D'Souza G, et al
    Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer.
    Oral Oncol. 2018;77:52-56.
    PubMed     Text format     Abstract available


  233. HUO M, Panizza B, Bernard A, Porceddu SV, et al
    Head and neck squamous cell carcinoma of unknown primary: Outcomes of a pre-defined institutional treatment policy in a region with a high prevalence of skin cancer.
    Oral Oncol. 2018;77:43-48.
    PubMed     Text format     Abstract available


  234. MAJERCAKOVA K, Valero C, Lopez M, Garcia J, et al
    Postoperative staging of the neck dissection using extracapsular spread and lymph node ratio as prognostic factors in HPV-negative head and neck squamous cell carcinoma patients.
    Oral Oncol. 2018;77:37-42.
    PubMed     Text format     Abstract available


  235. KLEIN NULENT TJW, Noorlag R, Van Cann EM, Pameijer FA, et al
    Intraoral ultrasonography to measure tumor thickness of oral cancer: A systematic review and meta-analysis.
    Oral Oncol. 2018;77:29-36.
    PubMed     Text format     Abstract available


  236. AU KH, Ngan RKC, Ng AWY, Poon DMC, et al
    Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study).
    Oral Oncol. 2018;77:16-21.
    PubMed     Text format     Abstract available


  237. VAN DEN BOVENKAMP K, Dorgelo B, Noordhuis MG, van der Laan BFAM, et al
    Viable tumor in salvage neck dissections in head and neck cancer: Relation with initial treatment, change of lymph node size and human papillomavirus.
    Oral Oncol. 2018;77:131-136.
    PubMed     Text format     Abstract available


  238. DE FELICE F, de Vincentiis M, Luzzi V, Magliulo G, et al
    Late radiation-associated dysphagia in head and neck cancer patients: evidence, research and management.
    Oral Oncol. 2018;77:125-130.
    PubMed     Text format     Abstract available


  239. YANG SF, Huang HD, Fan WL, Jong YJ, et al
    Compositional and functional variations of oral microbiota associated with the mutational changes in oral cancer.
    Oral Oncol. 2018;77:1-8.
    PubMed     Text format     Abstract available


    January 2018
  240. WANG Y, Qin X, Zhu X, Chen W, et al
    Corrigendum to "Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway" [Oral Oncol. 76 (2018) 34-41].
    Oral Oncol. 2018 Jan 25. pii: S1368-8375(18)30015.
    PubMed     Text format    


  241. XU T, Zhou X, Shen C, Hu C, et al
    Suggestions for surveillance and radiation strategy in nasopharyngeal carcinoma treated with IMRT: Based on hazard-rate and patterns of recurrence.
    Oral Oncol. 2018;76:61-67.
    PubMed     Text format     Abstract available


  242. SZTURZ P, Wouters K, Kiyota N, Tahara M, et al
    Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis.
    Oral Oncol. 2018;76:52-60.
    PubMed     Text format     Abstract available


  243. KUFTA K, Forman M, Swisher-McClure S, Sollecito TP, et al
    Pre-Radiation dental considerations and management for head and neck cancer patients.
    Oral Oncol. 2018;76:42-51.
    PubMed     Text format     Abstract available


  244. WANG Y, Qin X, Zhu X, Chen W, et al
    Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway.
    Oral Oncol. 2018;76:34-41.
    PubMed     Text format     Abstract available


  245. MARCAZZAN S, Varoni EM, Blanco E, Lodi G, et al
    Nanomedicine, an emerging therapeutic strategy for oral cancer therapy.
    Oral Oncol. 2018;76:1-7.
    PubMed     Text format     Abstract available


    December 2017
  246. VARELA-CENTELLES P, Garcia-Martin JM, Seoane-Romero J
    On the studies of time periods in head and neck cancer diagnosis and treatment.
    Oral Oncol. 2017 Dec 27. pii: S1368-8375(17)30415.
    PubMed     Text format    


  247. PENG H, Chen BB, Chen L, Chen YP, et al
    A network meta-analysis in comparing prophylactic treatments of radiotherapy-induced oral mucositis for patients with head and neck cancers receiving radiotherapy.
    Oral Oncol. 2017;75:89-94.
    PubMed     Text format     Abstract available


  248. VAN GINKEL JH, Slieker FJB, de Bree R, van Es RJJ, et al
    Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: A systematic review of the literature.
    Oral Oncol. 2017;75:8-15.
    PubMed     Text format     Abstract available


  249. KULASINGHE A, Kenny L, Punyadeera C
    Circulating tumour cell PD-L1 test for head and neck cancers.
    Oral Oncol. 2017;75:6-7.
    PubMed     Text format     Abstract available


  250. JOSHI A, Patil V, Noronha V, Dhumal S, et al
    Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.
    Oral Oncol. 2017;75:54-60.
    PubMed     Text format     Abstract available


  251. CHENG SJ, Chang CF, Ko HH, Liu YC, et al
    Hypermethylated ZNF582 and PAX1 genes in oral scrapings collected from cancer-adjacent normal oral mucosal sites are associated with aggressive progression and poor prognosis of oral cancer.
    Oral Oncol. 2017;75:169-177.
    PubMed     Text format     Abstract available


  252. CHHABRIA KS, Carnaby GD
    Psychometric validation of the Center for Epidemiological Studies Depression Scale in Head and Neck Cancer patients.
    Oral Oncol. 2017;75:158-162.
    PubMed     Text format     Abstract available


  253. LI WF, Zhang Y, Liu X, Tang LL, et al
    Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma.
    Oral Oncol. 2017;75:120-126.
    PubMed     Text format     Abstract available


  254. ASHIZAWA K, Yoshimura K, Johno H, Inoue T, et al
    Construction of mass spectra database and diagnosis algorithm for head and neck squamous cell carcinoma.
    Oral Oncol. 2017;75:111-119.
    PubMed     Text format     Abstract available


  255. KANG M, Zhou P, Liao X, Xu M, et al
    Prognostic value of masticatory muscle involvement in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
    Oral Oncol. 2017;75:100-105.
    PubMed     Text format     Abstract available


  256. PARK YM, Lee DY, Oh KH, Cho JG, et al
    Clinical implications of pathologic factors after thyroid lobectomy in patients with papillary thyroid carcinoma.
    Oral Oncol. 2017;75:1-5.
    PubMed     Text format     Abstract available


    November 2017
  257. RAJ AT, Patil S, Sarode SC, Sarode GS, et al
    Evaluating the association between household air pollution and oral cancer.
    Oral Oncol. 2017 Nov 11. pii: S1368-8375(17)30363.
    PubMed     Text format    


  258. ECONOMOPOULOU P, Kotsantis I, Kyrodimos E, Lianidou ES, et al
    Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).
    Oral Oncol. 2017;74:83-89.
    PubMed     Text format     Abstract available


  259. FADEN DL, Thomas S, Cantalupo PG, Agrawal N, et al
    Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;74:8-14.
    PubMed     Text format     Abstract available


  260. HAKANSSON K, Rasmussen JH, Rasmussen GB, Friborg J, et al
    A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments.
    Oral Oncol. 2017;74:77-82.
    PubMed     Text format     Abstract available


  261. SZTURZ P, Budikova M, Vermorken JB, Horova I, et al
    Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.
    Oral Oncol. 2017;74:68-76.
    PubMed     Text format     Abstract available


  262. WARD MC, Shah C, Adelstein DJ, Geiger JL, et al
    Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer.
    Oral Oncol. 2017;74:49-55.
    PubMed     Text format     Abstract available


  263. MI JL, Zhang B, Pan YF, Su YX, et al
    Chemotherapy regimens containing taxanes or fluorouracil in nasopharyngeal carcinoma: Which better?
    Oral Oncol. 2017;74:34-39.
    PubMed     Text format     Abstract available


  264. DIRVEN R, Ebrahimi A, Moeckelmann N, Palme CE, et al
    Tumor thickness versus depth of invasion - Analysis of the 8th edition American Joint Committee on Cancer Staging for oral cancer.
    Oral Oncol. 2017;74:30-33.
    PubMed     Text format     Abstract available


  265. AJMANI GS, Nocon CC, Wang CH, Bhayani MK, et al
    Assessment of adjuvant therapy in resected head and neck cancer with high-risk features.
    Oral Oncol. 2017;74:15-20.
    PubMed     Text format     Abstract available


  266. TAO Y, Gross N, Liu Y, Zhang L, et al
    A high ratio of IL-12Rbeta2-positive tumor-infiltrating lymphocytes indicates favorable prognosis in laryngeal cancer.
    Oral Oncol. 2017;74:148-156.
    PubMed     Text format     Abstract available


  267. BONOMO P, Desideri I, Loi M, Lo Russo M, et al
    Elderly patients affected by head and neck squamous cell carcinoma unfit for standard curative treatment: Is de-intensified, hypofractionated radiotherapy a feasible strategy?
    Oral Oncol. 2017;74:142-147.
    PubMed     Text format     Abstract available


  268. PAPAKOSTAS P, Tsaousi G, Stavrou G, Rachovitsas D, et al
    Percutaneous endoscopic gastrostomy feeding of locally advanced oro-pharygo-laryngeal cancer patients: Blenderized or commercial food?
    Oral Oncol. 2017;74:135-141.
    PubMed     Text format     Abstract available


  269. SU TL, Chen AN, Leong CP, Huang YC, et al
    The effect of home-based program and outpatient physical therapy in patients with head and neck cancer: A randomized, controlled trial.
    Oral Oncol. 2017;74:130-134.
    PubMed     Text format     Abstract available


  270. PATINO MA, Ramirez RE, Perez CA, Feng L, et al
    The impact of intraoperative opioid use on survival after oral cancer surgery.
    Oral Oncol. 2017;74:1-7.
    PubMed     Text format     Abstract available


    October 2017
  271. WU M, Ou D, He X, Hu C, et al
    Corrigendum to "Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma" [Oral Oncol. 73 (2017) 118-123].
    Oral Oncol. 2017 Oct 11. pii: S1368-8375(17)30306.
    PubMed     Text format     Abstract available


  272. LI YC, Chen FP, Zhou GQ, Zhu JH, et al
    Incidence and dosimetric parameters for brainstem necrosis following intensity modulated radiation therapy in nasopharyngeal carcinoma.
    Oral Oncol. 2017;73:97-104.
    PubMed     Text format     Abstract available


  273. TSAI MS, Chen WC, Lai CH, Chen YY, et al
    Epigenetic therapy regulates the expression of ALDH1 and immunologic response: Relevance to the prognosis of oral cancer.
    Oral Oncol. 2017;73:88-96.
    PubMed     Text format     Abstract available


  274. WU SG, Liao XL, He ZY, Tang LY, et al
    Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: A population-based analysis.
    Oral Oncol. 2017;73:83-87.
    PubMed     Text format     Abstract available


  275. HANNA GJ, Adkins DR, Zolkind P, Uppaluri R, et al
    Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;73:65-69.
    PubMed     Text format     Abstract available


  276. NAKANO K, Marshall S, Taira S, Sato Y, et al
    A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
    Oral Oncol. 2017;73:21-26.
    PubMed     Text format     Abstract available


  277. KIYOTA N, Hasegawa Y, Takahashi S, Yokota T, et al
    A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
    Oral Oncol. 2017;73:138-146.
    PubMed     Text format     Abstract available


  278. WU M, Ou D, He X, Hu C, et al
    Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2017;73:118-123.
    PubMed     Text format    


  279. FARQUHAR DR, Divaris K, Mazul AL, Weissler MC, et al
    Poor oral health affects survival in head and neck cancer.
    Oral Oncol. 2017;73:111-117.
    PubMed     Text format     Abstract available


  280. HUANG SF, Hsiao JH, Young CK, Chien HT, et al
    Familial aggregation of nasopharyngeal carcinoma in Taiwan.
    Oral Oncol. 2017;73:10-15.
    PubMed     Text format     Abstract available


  281. UPADHYAY P, Gardi N, Desai S, Chandrani P, et al
    Genomic characterization of tobacco/nut chewing HPV-negative early stage tongue tumors identify MMP10 asa candidate to predict metastases.
    Oral Oncol. 2017;73:56-64.
    PubMed     Text format     Abstract available


  282. SHARMA SJ, Wittekindt C, Knuth J, Steiner D, et al
    Intraindividual homogeneity of 18F-FDG PET/CT parameters in HPV-positive OPSCC.
    Oral Oncol. 2017;73:166-171.
    PubMed     Text format     Abstract available


  283. ZHAN KY, Eskander A, Kang SY, Old MO, et al
    Appraisal of the AJCC 8th edition pathologic staging modifications for HPV-positive oropharyngeal cancer, a study of the National Cancer Data Base.
    Oral Oncol. 2017;73:152-159.
    PubMed     Text format     Abstract available


    September 2017
  284. VEVE MP, Davis SL, Williams AM, McKinnon JE, et al
    Considerations for antibiotic prophylaxis in head and neck cancer surgery.
    Oral Oncol. 2017 Sep 21. pii: S1368-8375(17)30281.
    PubMed     Text format     Abstract available


  285. SAHOVALER A, Yeh D, Yoo J
    Primary facial reanimation in head and neck cancer.
    Oral Oncol. 2017 Sep 12. pii: S1368-8375(17)30246.
    PubMed     Text format     Abstract available


  286. OUYANG PY, Xiao Y, You KY, Zhang LN, et al
    Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi.
    Oral Oncol. 2017;72:65-72.
    PubMed     Text format     Abstract available


  287. KRISHNAN AR, Zheng H, Kwok JG, Qu Y, et al
    A comprehensive study of smoking-specific microRNA alterations in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;72:56-64.
    PubMed     Text format     Abstract available


  288. LI K, Yang L, Xin P, Chen Y, et al
    Impact of dose volume parameters and clinical factors on acute radiation oral mucositis for locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemoradiotherapy.
    Oral Oncol. 2017;72:32-37.
    PubMed     Text format     Abstract available


  289. ADKINS D, Ley J, Oppelt P, Wildes TM, et al
    nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2017;72:26-31.
    PubMed     Text format     Abstract available


  290. BROWN T, Banks M, Hughes BGM, Lin C, et al
    Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer.
    Oral Oncol. 2017;72:17-25.
    PubMed     Text format     Abstract available


  291. BROWN T, Banks M, Hughes BGM, Lin C, et al
    Tube feeding during treatment for head and neck cancer - Adherence and patient reported barriers.
    Oral Oncol. 2017;72:140-149.
    PubMed     Text format     Abstract available


  292. ALEXANDER-BRYANT AA, Zhang H, Attaway CC, Pugh W, et al
    Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo.
    Oral Oncol. 2017;72:123-131.
    PubMed     Text format     Abstract available


  293. STOKES WA, Stumpf PK, Jones BL, Blatchford PJ, et al
    Patterns of fractionation for patients with T2N0M0 glottic larynx cancer undergoing definitive radiotherapy in the United States.
    Oral Oncol. 2017;72:110-116.
    PubMed     Text format     Abstract available


  294. ALSIDAWI S, Price KA, Chintakuntlawar AV, Westin GF, et al
    Characteristics and long-term outcomes of head and neck squamous cell carcinoma after solid organ transplantation.
    Oral Oncol. 2017;72:104-109.
    PubMed     Text format     Abstract available


  295. DONA MG, Rollo F, Pichi B, Spriano G, et al
    Evaluation of the Xpert(R) HPV assay in the detection of Human Papillomavirus in formalin-fixed paraffin-embedded oropharyngeal carcinomas.
    Oral Oncol. 2017;72:117-122.
    PubMed     Text format     Abstract available


    August 2017
  296. SAFIRI S, Ayubi E
    Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease: Methodological issues.
    Oral Oncol. 2017;71:95.
    PubMed     Text format    


  297. MORISADA M, Moore EC, Hodge R, Friedman J, et al
    Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer.
    Oral Oncol. 2017;71:87-94.
    PubMed     Text format     Abstract available


  298. KIM TH, Kim YN, Kim HI, Park SY, et al
    Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma.
    Oral Oncol. 2017;71:81-86.
    PubMed     Text format     Abstract available


  299. ARRIBAS L, Hurtos L, Taberna M, Peiro I, et al
    Nutritional changes in patients with locally advanced head and neck cancer during treatment.
    Oral Oncol. 2017;71:67-74.
    PubMed     Text format     Abstract available


  300. TAO Y, Auperin A, Graff P, Lapeyre M, et al
    Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
    Oral Oncol. 2017;71:61-66.
    PubMed     Text format     Abstract available


  301. KITANI Y, Kubota A, Furukawa M, Hori Y, et al
    Impact of combined modality treatment with radiotherapy and S-1 on T2N0 laryngeal cancer: Possible improvement in survival through the prevention of second primary cancer and distant metastasis.
    Oral Oncol. 2017;71:54-59.
    PubMed     Text format     Abstract available


  302. MATOS LL, Dedivitis RA, Kulcsar MAV, de Mello ES, et al
    External validation of the AJCC Cancer Staging Manual, 8th edition, in an independent cohort of oral cancer patients.
    Oral Oncol. 2017;71:47-53.
    PubMed     Text format     Abstract available


  303. MASSA ST, Osazuwa-Peters N, Franco J, Ward GW, et al
    Survival after refusal of surgical treatment for locally advanced laryngeal cancer.
    Oral Oncol. 2017;71:34-40.
    PubMed     Text format     Abstract available


  304. WENDRICH AW, Swartz JE, Bril SI, Wegner I, et al
    Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer.
    Oral Oncol. 2017;71:26-33.
    PubMed     Text format     Abstract available


  305. OOFT ML, van Ipenburg JA, Braunius WW, Zuur CI, et al
    Prognostic role of tumor infiltrating lymphocytes in EBV positive and EBV negative nasopharyngeal carcinoma.
    Oral Oncol. 2017;71:16-25.
    PubMed     Text format     Abstract available


  306. HINGORANI DV, Lemieux AJ, Acevedo JR, Glasgow HL, et al
    Early detection of squamous cell carcinoma in carcinogen induced oral cancer rodent model by ratiometric activatable cell penetrating peptides.
    Oral Oncol. 2017;71:156-162.
    PubMed     Text format     Abstract available


  307. OU D, Blanchard P, Rosellini S, Levy A, et al
    Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
    Oral Oncol. 2017;71:150-155.
    PubMed     Text format     Abstract available


  308. BRYERE J, Menvielle G, Dejardin O, Launay L, et al
    Neighborhood deprivation and risk of head and neck cancer: A multilevel analysis from France.
    Oral Oncol. 2017;71:144-149.
    PubMed     Text format     Abstract available


  309. PARK YM, Jung CM, Cha D, Kim SH, et al
    The long-term oncological and functional outcomes of transoral robotic surgery in patients with hypopharyngeal cancer.
    Oral Oncol. 2017;71:138-143.
    PubMed     Text format     Abstract available


  310. DONG Y, Ridge JA, Li T, Lango MN, et al
    Long-term toxicities in 10-year survivors of radiation treatment for head and neck cancer.
    Oral Oncol. 2017;71:122-128.
    PubMed     Text format     Abstract available


  311. GIULIANI M, Milne R, McQuestion M, Sampson L, et al
    Partner's survivorship care needs: An analysis in head and neck cancer patients.
    Oral Oncol. 2017;71:113-121.
    PubMed     Text format     Abstract available


  312. ANTUNES HS, Herchenhorn D, Small IA, Araujo CMM, et al
    Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis.
    Oral Oncol. 2017;71:11-15.
    PubMed     Text format     Abstract available


  313. CHEN MM, Orosco RK, Harris JP, Porter JB, et al
    Predictors of readmissions after head and neck cancer surgery: A national perspective.
    Oral Oncol. 2017;71:106-112.
    PubMed     Text format     Abstract available


  314. JERZAK KJ, Delos Santos K, Saluja R, Lien K, et al
    A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN).
    Oral Oncol. 2017;71:1-10.
    PubMed     Text format     Abstract available


    July 2017
  315. BAIS MV, Kukuruzinska M, Trackman PC
    Corrigendum to "Orthotopic non-metastatic and metastatic oral cancer mouse models" [Oral Oncol. 51(5) (2015) 476-482].
    Oral Oncol. 2017 Jul 22. pii: S1368-8375(17)30198.
    PubMed     Text format    


  316. CHAN JYW, Chan RCL, Chow VLY, Tsang RKY, et al
    Transoral robotic total laryngopharyngectomy and free jejunal flap reconstruction for hypopharyngeal cancer.
    Oral Oncol. 2017 Jul 15. pii: S1368-8375(17)30187.
    PubMed     Text format     Abstract available


  317. KE LR, Xia WX, Qiu WZ, Huang XJ, et al
    A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2017;70:7-13.
    PubMed     Text format     Abstract available


  318. JI YB, Song CM, Bang HS, Park HJ, et al
    Functional and cosmetic outcomes of robot-assisted neck dissection by a postauricular facelift approach for head and neck cancer.
    Oral Oncol. 2017;70:51-57.
    PubMed     Text format     Abstract available


  319. DE MEULENAERE A, Vermassen T, Aspeslagh S, Huvenne W, et al
    Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;70:34-42.
    PubMed     Text format     Abstract available


  320. ALI J, Sabiha B, Jan HU, Haider SA, et al
    Genetic etiology of oral cancer.
    Oral Oncol. 2017;70:23-28.
    PubMed     Text format     Abstract available


  321. BROGLIE MA, Jochum W, Michel A, Waterboer T, et al
    Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer.
    Oral Oncol. 2017;70:43-50.
    PubMed     Text format     Abstract available


    June 2017
  322. LE QT, Welch JJ, Vermorken JB, Rischin D, et al
    Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG.
    Oral Oncol. 2017 Jun 22. pii: S1368-8375(17)30139.
    PubMed     Text format     Abstract available


  323. XU C, Chen YP, Liu X, Li WF, et al
    Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.
    Oral Oncol. 2017;69:99-107.
    PubMed     Text format     Abstract available


  324. AI QY, King AD, Mo FKF, Law BKH, et al
    Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease.
    Oral Oncol. 2017;69:74-79.
    PubMed     Text format     Abstract available


  325. TANG LL, Tang XR, Li WF, Chen L, et al
    The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement.
    Oral Oncol. 2017;69:68-73.
    PubMed     Text format     Abstract available


  326. ADAMI GR, Tang JL, Markiewicz MR
    Improving accuracy of RNA-based diagnosis and prognosis of oral cancer by using noninvasive methods.
    Oral Oncol. 2017;69:62-67.
    PubMed     Text format     Abstract available


  327. LAPRISE C, Madathil SA, Schlecht NF, Castonguay G, et al
    Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study.
    Oral Oncol. 2017;69:56-61.
    PubMed     Text format     Abstract available


  328. STABILE LP, Egloff AM, Gibson MK, Gooding WE, et al
    IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
    Oral Oncol. 2017;69:38-45.
    PubMed     Text format     Abstract available


  329. WU LR, Liu YT, Jiang N, Fan YX, et al
    Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: An analysis of 614 patients from a single center.
    Oral Oncol. 2017;69:26-32.
    PubMed     Text format     Abstract available


  330. WICHMANN G, Herchenhahn C, Boehm A, Mozet C, et al
    HLA traits linked to development of head and neck squamous cell carcinoma affect the progression-free survival of patients.
    Oral Oncol. 2017;69:115-127.
    PubMed     Text format     Abstract available


  331. CHEN CC, Lin JC, Chen KW
    Comparison cisplatin with cisplatin plus 5FU in head and neck cancer patients received postoperative chemoradiotherapy.
    Oral Oncol. 2017;69:11-14.
    PubMed     Text format     Abstract available


  332. DABAS S, Gupta K, Ranjan R, Sharma AK, et al
    Oncological outcome following de-intensification of treatment for stage I and II HPV negative oropharyngeal cancers with transoral robotic surgery (TORS): A prospective trial.
    Oral Oncol. 2017;69:80-83.
    PubMed     Text format     Abstract available


    May 2017
  333. CHOUGULE A, Patil VM, Noronha V, Joshi A, et al
    Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers.
    Oral Oncol. 2017 May 22. pii: S1368-8375(17)30115.
    PubMed     Text format    


  334. SHAIKH MH, Clarke DTW, Johnson NW, McMillan NAJ, et al
    Can gene editing and silencing technologies play a role in the treatment of head and neck cancer?
    Oral Oncol. 2017;68:9-19.
    PubMed     Text format     Abstract available


  335. NOIJ DP, Martens RM, Marcus JT, de Bree R, et al
    Intravoxel incoherent motion magnetic resonance imaging in head and neck cancer: A systematic review of the diagnostic and prognostic value.
    Oral Oncol. 2017;68:81-91.
    PubMed     Text format     Abstract available


  336. ZHAI RP, Kong FF, Du CR, Hu CS, et al
    Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study.
    Oral Oncol. 2017;68:44-49.
    PubMed     Text format     Abstract available


  337. HUANG TT, Huang JS, Wang YY, Chen KC, et al
    Novel quantitative analysis of autofluorescence images for oral cancer screening.
    Oral Oncol. 2017;68:20-26.
    PubMed     Text format     Abstract available


  338. DODD RH, Forster AS, Waller J, Marlow LAV, et al
    Discussing HPV with oropharyngeal cancer patients: A cross-sectional survey of attitudes in health professionals.
    Oral Oncol. 2017;68:67-73.
    PubMed     Text format     Abstract available


    April 2017
  339. RUEDA A, Giralt J, Manos M, Lozano A, et al
    Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2).
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30087.
    PubMed     Text format     Abstract available


  340. MANOS M, Giralt J, Rueda A, Cabrera J, et al
    Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1).
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30088.
    PubMed     Text format     Abstract available


  341. AYUBI E, Safiri S
    Lateral lymph node recurrence after total thyroidectomy and central neck dissection in patients with papillary thyroid cancer without clinical evidence of lateral neck metastasis: Comment on data sparsity.
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30086.
    PubMed     Text format    


  342. YANG Q, Zou X, You R, Liu YP, et al
    Proposal for a new risk classification system for nasopharyngeal carcinoma patients with post-radiation nasopharyngeal necrosis.
    Oral Oncol. 2017;67:83-88.
    PubMed     Text format     Abstract available


  343. BORCHIELLINI D, Etienne-Grimaldi MC, Bensadoun RJ, Benezery K, et al
    Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer.
    Oral Oncol. 2017;67:70-76.
    PubMed     Text format     Abstract available


  344. HANNA GJ, Liu H, Jones RE, Bacay AF, et al
    Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;67:61-69.
    PubMed     Text format     Abstract available


  345. OUYANG PY, Zhang LN, Xiao Y, Lan XW, et al
    Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma.
    Oral Oncol. 2017;67:37-45.
    PubMed     Text format     Abstract available


  346. PEREZ CA, Wu X, Amsbaugh MJ, Gosain R, et al
    High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;67:24-28.
    PubMed     Text format     Abstract available


  347. KINDT N, Descamps G, Seminerio I, Bellier J, et al
    High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;67:183-191.
    PubMed     Text format     Abstract available


  348. POLESEL J, Furlan C, Birri S, Giacomarra V, et al
    The impact of time to treatment initiation on survival from head and neck cancer in north-eastern Italy.
    Oral Oncol. 2017;67:175-182.
    PubMed     Text format     Abstract available


  349. XIA WX, Liang H, Lv X, Wang L, et al
    Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis.
    Oral Oncol. 2017;67:167-174.
    PubMed     Text format     Abstract available


  350. CHAU L, Jabara JT, Lai W, Svider PF, et al
    Topical agents for oral cancer chemoprevention: A systematic review of the literature.
    Oral Oncol. 2017;67:153-159.
    PubMed     Text format     Abstract available


  351. DE FELICE F, Guerrero Urbano T
    New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
    Oral Oncol. 2017;67:119-123.
    PubMed     Text format     Abstract available


  352. KADLETZ L, Thurnher D, Wiebringhaus R, Erovic BM, et al
    Role of cancer stem-cell marker doublecortin-like kinase 1 in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;67:109-118.
    PubMed     Text format     Abstract available


  353. KOFLER B, Borena W, Manzl C, Dudas J, et al
    Sensitivity of tumor surface brushings to detect human papilloma virus DNA in head and neck cancer.
    Oral Oncol. 2017;67:103-108.
    PubMed     Text format     Abstract available


  354. RASTOGI M, Sapru S, Gupta P, Gandhi AK, et al
    Prospective evaluation of Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost (IMRT-SIB) in head and neck squamous cell carcinoma in patients not suitable for chemo-radiotherapy.
    Oral Oncol. 2017;67:10-16.
    PubMed     Text format     Abstract available


  355. HAMOIR M, Holvoet E, Ambroise J, Lengele B, et al
    Salvage surgery in recurrent head and neck squamous cell carcinoma: Oncologic outcome and predictors of disease free survival.
    Oral Oncol. 2017;67:1-9.
    PubMed     Text format     Abstract available


  356. LIAO CT, Wen YW, Yang LY, Lee SR, et al
    Comparative clinical outcomes of Taiwanese patients with resected buccal and tongue squamous cell carcinomas.
    Oral Oncol. 2017;67:95-102.
    PubMed     Text format     Abstract available


  357. LEVI S, Zini A, Fischman S, Czerninski R, et al
    Epidemiology of oral, salivary gland and pharyngeal cancer in children and adolescents between 1970 and 2011.
    Oral Oncol. 2017;67:89-94.
    PubMed     Text format     Abstract available


  358. ZHANG Y, Waterboer T, Haddad RI, Miles BA, et al
    Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment.
    Oral Oncol. 2017;67:77-82.
    PubMed     Text format     Abstract available


  359. CHAN OS, Kowanetz M, Ng WT, Koeppen H, et al
    Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.
    Oral Oncol. 2017;67:52-60.
    PubMed     Text format     Abstract available


  360. VELEZ MA, Veruttipong D, Wang PC, Chin R, et al
    Re-irradiation for recurrent and second primary cancers of the head and neck.
    Oral Oncol. 2017;67:46-51.
    PubMed     Text format     Abstract available


  361. LACAU ST GUILY J, Rousseau A, Baujat B, Perie S, et al
    Oropharyngeal cancer prognosis by tumour HPV status in France: The multicentric Papillophar study.
    Oral Oncol. 2017;67:29-36.
    PubMed     Text format     Abstract available


  362. KATO MG, Erkul E, Brewer KS, Harruff EE, et al
    Clinical features of ectomesenchymal chondromyxoid tumors: A systematic review of the literature.
    Oral Oncol. 2017;67:192-197.
    PubMed     Text format     Abstract available


  363. ALLI N, Meer S
    Head and neck lymphomas: A 20-year review in an Oral Pathology Unit, Johannesburg, South Africa, a country with the highest global incidence of HIV/AIDS.
    Oral Oncol. 2017;67:17-23.
    PubMed     Text format     Abstract available


  364. HAY A, Migliacci J, Karassawa Zanoni D, Boyle JO, et al
    Complications following transoral robotic surgery (TORS): A detailed institutional review of complications.
    Oral Oncol. 2017;67:160-166.
    PubMed     Text format     Abstract available


  365. TOTA JE, Anderson WF, Coffey C, Califano J, et al
    Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012.
    Oral Oncol. 2017;67:146-152.
    PubMed     Text format     Abstract available


  366. GISSI DB, Tarsitano A, Leonardi E, Gabusi A, et al
    Clonal analysis as a prognostic factor in multiple oral squamous cell carcinoma.
    Oral Oncol. 2017;67:131-137.
    PubMed     Text format     Abstract available


  367. KARATAS OF, Oner M, Abay A, Diyapoglu A, et al
    MicroRNAs in human tongue squamous cell carcinoma: From pathogenesis to therapeutic implications.
    Oral Oncol. 2017;67:124-130.
    PubMed     Text format     Abstract available


    March 2017
  368. PORCEDDU SV, Milne R, Brown E, Bernard A, et al
    Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy.
    Oral Oncol. 2017;66:81-86.
    PubMed     Text format     Abstract available


    February 2017
  369. GIRELLI L, Locati L, Galeone C, Scanagatta P, et al
    Lung metastasectomy in adenoid cystic cancer: Is it worth it?
    Oral Oncol. 2017;65:114-118.
    PubMed     Text format     Abstract available


  370. GELTZEILER M, Clayburgh D, Gleysteen J, Gross ND, et al
    Predictors of extracapsular extension in HPV-associated oropharyngeal cancer treated surgically.
    Oral Oncol. 2017;65:89-93.
    PubMed     Text format     Abstract available


  371. VAN GENECHTEN ML, Batstone MD
    The fate of the free flap pedicle after free tissue transfer to the head and neck area.
    Oral Oncol. 2017;65:65-67.
    PubMed     Text format     Abstract available


  372. MERY B, Rancoule C, Guy JB, Espenel S, et al
    Preclinical models in HNSCC: A comprehensive review.
    Oral Oncol. 2017;65:51-56.
    PubMed     Text format     Abstract available


  373. GENTILE MS, Yip D, Liebsch NJ, Adams JA, et al
    Definitive proton beam therapy for adenoid cystic carcinoma of the nasopharynx involving the base of skull.
    Oral Oncol. 2017;65:38-44.
    PubMed     Text format     Abstract available


  374. NARUSE T, Yanamoto S, Okuyama K, Yamashita K, et al
    Therapeutic implication of mTORC2 in oral squamous cell carcinoma.
    Oral Oncol. 2017;65:23-32.
    PubMed     Text format     Abstract available


  375. VASSILIOU LV, Lalabekyan B, Jay A, Liew C, et al
    Head and neck sarcomas: A single institute series.
    Oral Oncol. 2017;65:16-22.
    PubMed     Text format     Abstract available


  376. TAM AA, Ozdemir D, Cuhaci N, Baser H, et al
    Can ratio of the biggest tumor diameter to total tumor diameter be a new parameter in the differential diagnosis of agressive and favorable multifocal papillary thyroid microcarcinoma?
    Oral Oncol. 2017;65:1-7.
    PubMed     Text format     Abstract available


  377. LOMBARDI D, McGurk M, Vander Poorten V, Guzzo M, et al
    Surgical treatment of salivary malignant tumors.
    Oral Oncol. 2017;65:102-113.
    PubMed     Text format     Abstract available


    January 2017
  378. O'HARE J, Maclean J, Szczesniak M, Gupta R, et al
    Laryngeal tumours and radiotherapy dose to the cricopharyngeus are predictive of death from aspiration pneumonia.
    Oral Oncol. 2017;64:9-14.
    PubMed     Text format     Abstract available


  379. SHAW R, Tesfaye B, Bickerstaff M, Silcocks P, et al
    Refining the definition of mandibular osteoradionecrosis in clinical trials: The cancer research UK HOPON trial (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis).
    Oral Oncol. 2017;64:73-77.
    PubMed     Text format     Abstract available


  380. OWOSHO AA, Tsai CJ, Lee RS, Freymiller H, et al
    The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience.
    Oral Oncol. 2017;64:44-51.
    PubMed     Text format     Abstract available


  381. MARTEL M, Alemany L, Taberna M, Mena M, et al
    The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma.
    Oral Oncol. 2017;64:37-43.
    PubMed     Text format     Abstract available


  382. YAMADA SI, Kurita H, Tomioka T, Ohta R, et al
    Healthy life expectancy of oral squamous cell carcinoma patients aged 75years and older.
    Oral Oncol. 2017;64:22-26.
    PubMed     Text format     Abstract available


    December 2016
  383. JEANNON JP, Tanaka A, Thavaraj S, Guerrero-Urbano T, et al
    ATR gene mutations in HPV negative oropharyngeal cancer.
    Oral Oncol. 2016 Dec 22. pii: S1368-8375(16)30244.
    PubMed     Text format    


  384. CHERA B, Wang K, Monroe A, Galloway T, et al
    Truth or myth: Definitive chemoradiotherapy doesn't work for HPV/p16 negative oropharyngeal squamous cell carcinoma?
    Oral Oncol. 2016 Dec 16. pii: S1368-8375(16)30234.
    PubMed     Text format    


    November 2016
  385. HAUGHEY BH, Sinha P, Kallogjeri D, Goldberg RL, et al
    Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx.
    Oral Oncol. 2016;62:11-19.
    PubMed     Text format     Abstract available


  386. MIRGHANI H, Casiraghi O, Guerlain J, Amen F, et al
    Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test.
    Oral Oncol. 2016;62:101-108.
    PubMed     Text format     Abstract available


    September 2016
  387. D'SOUZA G, Zhang Y, Merritt S, Gold D, et al
    Patient experience and anxiety during and after treatment for an HPV-related oropharyngeal cancer.
    Oral Oncol. 2016;60:90-5.
    PubMed     Text format     Abstract available


  388. CHATURVEDI AK, D'Souza G, Gillison ML, Katki HA, et al
    Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population.
    Oral Oncol. 2016;60:61-7.
    PubMed     Text format     Abstract available


    July 2016
  389. SABER CN, Gronhoj Larsen C, Dalianis T, von Buchwald C, et al
    Immune cells and prognosis in HPV-associated oropharyngeal squamous cell carcinomas: Review of the literature.
    Oral Oncol. 2016;58:8-13.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: